784
Views
9
CrossRef citations to date
0
Altmetric
Review

A drug safety review of treating eosinophilic asthma with monoclonal antibodies

ORCID Icon &
Pages 1161-1170 | Received 05 Jul 2019, Accepted 30 Sep 2019, Published online: 21 Oct 2019
 

ABSTRACT

Introduction: The last two decades have seen significant progress in the treatment of severe asthma especially the severe eosinophilic phenotype. This review article serves to update the reader on the known safety profiles of these medications. It does not serve as a review of their clinical efficacies.

Areas covered: All four of the currently approved monoclonal antibodies (biologics) used in the treatment of severe asthma are discussed with reference to the known safety data garnered from clinical trials and real world evidence. A fifth, approved by The European Commission and FDA, but not yet by NICE or Health Canada, is also discussed.

Expert opinion: For each of the five biologics the authors shall summarize the known safety profiles and also the potential adverse effects as their usage is extended long term with suggestions for real world studies to help us develop our knowledge base.

Article highlights

  • Summary of safety data from phase III clinical trials, product monographs and real world evidence publications on the currently available biologics for the treatment of asthma

  • Safety review of cardiovascular, neoplastic, anaphylaxis risk profile of omalizumab

  • Safety review of the use of omalizumab in pregnancy

  • Safety review of the anti-IL 5 monoclonal antibodies, mepolizumab, reslizumab, and benralizumab

  • Safety review of the anti-IL 4/13 monoclonal antibody, dupilumab

This box summarizes key points contained in the article.

Author contributions

PDM authored the paper. RL coauthored the paper and provide expert feedback.

Declaration of interest

P Mitchell has received speaker fees from GlaxoSmithKline, AstraZeneca, Teva and Novartis, and has received grants from AstraZeneca and Teva. R Leigh has received consulting fees from AstraZeneca and speakers fees from Novartis. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper is not funded.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 752.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.